HOUSTON, March 13,
2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq:
FBLG) ("FibroBiologics"), a clinical-stage biotechnology
company with 150+ patents issued and pending with a focus on the
development of therapeutics and potential cures for chronic
diseases using fibroblasts and fibroblast-derived materials,
announced that it will present an oral and poster presentation at
the Advanced Wound Care Summit USA
in Boston, Massachusetts, from
April 16-17, 2024. The Advanced Wound
Care Summit USA is a forum where
industry leaders share the latest innovations and advancements in
Wound Care and tackle pressing challenges in areas such as
regulation, clinical trials, reimbursement, and investment.
FibroBiologics will be represented by Chief Scientific Officer,
Hamid Khoja, Ph.D., and Associate
Scientist, Subhiksha Raghuram, MS, MD, who will present on
FibroBiologics' fibroblast cell therapies and their potential to
treat chronic wounds.
Details of the presentations are as follows:
Oral Presentation:
Presentation Title:
Fibroblast Spheroid-mediated Accelerated Chronic Wound Healing in a
Diabetic Mouse Model
Presenter: Hamid Khoja,
Ph.D., Chief Scientific Officer, FibroBiologics
Session Title: Research and Development - Biologics
Session Date and Time: April 16, 2024, at 12:20 p.m. Eastern Standard Time
Poster Presentation:
Presentation Title:
Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds
in a Diabetes Mouse Model
Presenter: Subhiksha
Raghuram, MS, MD, Associate Scientist, FibroBiologics
Poster Session: Available Virtually
"The data we will present highlights the clinical potential of
fibroblast cell-based treatment for chronic wounds such as diabetic
foot ulcers and venous ulcers," said Dr. Khoja. "Fibroblasts are
key participants in every single stage of wound healing. We believe
that by harnessing the specific capacity of fibroblasts in wound
healing, we have the potential of revolutionizing wound care as we
know it. We look forward to attending the meeting to share our
data, and connecting with fellow experts in the field."
For more information, please visit FibroBiologics' website or
email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning the
potential of fibroblast cell therapies to treat chronic wounds such
as diabetic foot ulcers, and venous ulcers, and the potential of
such treatments to revolutionize wound care by harnessing the
specific capacity of fibroblasts in wound healing. These
forward-looking statements are based on FibroBiologics'
management's current expectations, estimates, projections and
beliefs, as well as a number of assumptions concerning future
events. When used in this communication, the words "estimates,"
"projected," "expects," "anticipates," "forecasts," "plans,"
"intends," "believes," "seeks," "may," "will," "should," "future,"
"propose" and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements. These forward-looking
statements are not guarantees of future performance, conditions or
results, and involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of
which are outside FibroBiologics' management's control, that could
cause actual results to differ materially from the results
discussed in the forward-looking statements, including those set
forth under the caption "Risk Factors" and elsewhere in
FibroBiologics' annual, quarterly and current reports (i.e., Form
10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC
and any subsequent public filings. Copies are available on the
SEC's website, www.sec.gov. These risks, uncertainties,
assumptions and other important factors include, but are not
limited to: (a) the ability of FibroBiologics to continue to meet
Nasdaq listing requirements; (b) risks related to FibroBiologics'
liquidity and its ability to maintain capital resources sufficient
to conduct its business; and (c) the ability to effectively manage
the business as a result of the super-voting proxy given to the
Board of Directors. Forward-looking statements speak only as of the
date they are made. Readers are cautioned not to put undue reliance
on forward-looking statements, and FibroBiologics assumes no
obligation and, except as required by law, does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise.
FibroBiologics gives no assurance that it will achieve its
expectations.
About FibroBiologics
Based in Houston,
FibroBiologics is a cell therapy and regenerative medicine company
developing a pipeline of treatments and seeking potential cures for
chronic diseases using fibroblast cells and fibroblast-derived
materials. FibroBiologics holds 150+ US and internationally issued
patents/patents pending across various clinical pathways, including
disc degeneration, orthopedics, multiple sclerosis, wound healing,
reversing organ involution, and cancer. FibroBiologics represents
the next generation of medical advancement in cell therapy. For
more information, visit www.FibroBiologics.com.
Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
(646) 942-5599
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
General Inquiries:
info@fibrobiologics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-to-present-at-advanced-wound-care-summit-usa-302087502.html
SOURCE FibroBiologics